Biolight controlling shareholder Yan Jinyuan is planning a change of control. Trading in the company's shares and convertible bonds has been suspended since the market opened on August 3, with the suspension expected to last no more than two trading days. On the last trading day before the suspension, Biolight's stock price closed at 19.26 yuan per share, up 10.37%, giving it a total market value of 5.096 billion yuan. In January this year, Yan Jinyuan and his wife Wang Shi transferred a combined 18.5206 million Biolight shares, representing 7% of the company's total share capital, to Zhejiang Quwei Zhihe Holding Partnership at a price of 9.45 yuan per share through a negotiated transfer. The transaction was completed on May 28, making Quwei Zhihe the second-largest shareholder of Biolight. Biolight has been reporting losses in recent years, with net profit attributable to the parent company of minus 65.1851 million yuan in 2023, minus 71.4413 million yuan in 2024, and minus 69.4278 million yuan in 2025. In the first quarter of 2026, net profit attributable to the parent company was minus 7.3189 million yuan, a year-on-year decline of 150.66%.
Guangdong Biolight Meditech Co LtdControlling shareholder plans change of control; stock surged before suspension, but outcome and terms unknown.